Skip to main content

Gene Therapy to restore lymphatic flow lymphedema

Project description

Novel gene therapy approach to treat lymphedema

Lymphedema is a disabling condition of localised accumulation of fluid in a tissue caused by a compromised lymphatic system. It is an incurable disease that affects millions of people worldwide and is most often a consequence of cancer treatment. The main objective of the EU-funded TheraLymph project is to develop treatment to ameliorate this condition using a non-integrative gene therapy approach. The project consortium's translational research programme brings together scientists and physicians from 5 European countries and will be focused on patients who developed lymphedema after breast cancer. Research will determine risk factors for lymphedema and key molecular players involved in the lymphatic dysfunction. The project goal is to validate the best molecule combination for gene therapy and to finalise phase I/II clinical trials at the affiliated hospital.

Field of science

  • /natural sciences/earth and related environmental sciences/physical geography/cartography
  • /medical and health sciences/medical biotechnology/genetic engineering/gene therapy
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/cardiology/cardiovascular diseases
  • /medical and health sciences/clinical medicine/oncology/cancer/breast cancer

Call for proposal

H2020-SC1-2019-Single-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 1 475 531,25

Participants (10)

HELSINGIN YLIOPISTO
Finland
EU contribution
€ 1 046 198,75
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Activity type
Higher or Secondary Education Establishments
UNIVERSITE DE LAUSANNE
Switzerland
EU contribution
€ 868 185
Address
Quartier Unil-centre Bâtiment Unicentre
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 455 000
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
DE DUVE INSTITUTE AISBL
Belgium
EU contribution
€ 608 335
Address
Avenue Hippocrate 75/50
1200 Bruxelles
Activity type
Research Organisations
UNIVERSITE DE LIEGE
Belgium
EU contribution
€ 706 250
Address
Place Du 20 Aout 7
4000 Liege
Activity type
Higher or Secondary Education Establishments
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 317 287,50
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations
UNIVERZITA KARLOVA
Czechia
EU contribution
€ 293 750
Address
Ovocny Trh 560/5
116 36 Praha 1
Activity type
Higher or Secondary Education Establishments
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
France
EU contribution
€ 947 000
Address
Rue Viguerie 2 Hotel Dieu Saint Jacques
31052 Toulouse Cedex 3
Activity type
Higher or Secondary Education Establishments
FLASH THERAPEUTICS
France
EU contribution
€ 1 132 908,50
Address
Canal Biotech Ii - 3 Rue Des Satellites
31400 Toulouse
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSERM TRANSFERT SA
France
EU contribution
€ 214 500
Address
Rue Watt 7
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)